Authors: Calusic M, Marcec R, Luksa L, Jurkovic I, Kovac N, Likic R PMID: 34719789 PMCID: PMC8653355 DOI: 10.1111/bcp.15126 Abstract Aims: Fluvoxamine, a selective serotonin reuptake inhibitor (SSRI) and sigma-1 receptor agonist, has so far shown promise in the prevention of COVID-19 progression as an early treatment option in three trials. The aim of this [...]

Authors: Reis G, Moreira-Silva EA, Silva DC, Thabane L, Guyatt GH, Mills EJ PMID: 34717820 PMCID: PMC8550952 DOI: 10.1016/S2214-109X(21)00448-4 Abstract Background: Recent evidence indicates a potential therapeutic role of fluvoxamine for COVID-19. In the TOGETHER trial for acutely symptomatic patients with COVID-19, we aimed to assess the efficacy of fluvoxamine versus placebo in preventing hospitalisation [...]

Authors: Sukhatme VP, Reiersen AM, Vayttaden SJ, Sukhatme VV doi: https://doi.org/10.3389/fphar.2021.652688 Abstract Fluvoxamine is a well-tolerated, widely available, inexpensive selective serotonin reuptake inhibitor that has been shown in a small, double-blind, placebo-controlled, randomized study to prevent clinical deterioration of patients with mild coronavirus disease 2019 (COVID-19). Fluvoxamine is also an agonist for the sigma-1 receptor, [...]